It always helps when they triple - long VSTM at 9.24VSTM is not normally on my radar screen - it's a small cap and I don't trade a bunch of those. Also, zoom out all the way and you'll see that this one is not without its risks. It is a stock that does not turn a profit. So in the event anyone follows me on this one, consider yourself warned. This is a trade, not an investment.
That said, in a rate cut environment, small caps should outperform and this one is already doing that. I will not apologize for the results I'm about to share. Yes, the stock is up over 3x during this span. But I'm not a buy and holder, and if you're gonna be long, it's best to do it in stocks that are going up - agreed? By the way, the 9.24 entry is after hours. I ran out of time during the regular session - today was a busy day.
So here it is - last 12M:
20 signals: 19 wins, 1 loss (still open)
AVERAGE gain = +8.85%
40% of the trades have made > 10%
average holding period = 10.5 days
Avg gain per lot per day held = 0.84%
BTW - the numbers on the arrows are on the chart are basis points. For those not familiar 1 basis point = .01%, so 252bp = 2.52%. I am just tired of typing the extra 2 characters for the decimal point and % on all of those.
I will potentially tactically add here, but in a more limited way than I otherwise would. A small cap like this can potentially sink your whole ship if you keep throwing money at it if it is sinking. I will also not hesitate to take profits along the way. This is a classic example of how nothing in the market comes for free. Yes it produces fat returns, but it also carries fat risk, so I need to approach it accordingly. Also, I have not done a full backtest on this one yet. Hopefully I can do that tonight and I'll post the results as a note here.
As always - this is intended as "edutainment" and my perspective on what I am or would be doing, not a recommendation for you to buy or sell. Act accordingly and invest at your own risk. DYOR and only make investments that make good financial sense for you in your current situation.
VSTM trade ideas
FDA gave breakthrough designation..Verastem announced it received FDA Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer.
If the flag holds, it looks like it could hit around $4.60. Considering adding to my position today. But probably will just hold with what I have.
$VSTM Verastem, Inc., Potential 20% UpsideVerastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
$VSTM Bullish opportunity targeting double current price 1.48Bullish setup formed by 3 red daily candles closing at same price . this pattern can lead to significant price change and RSI signal positively .. bullish long more likely with stoploss at 1.25 (not far away) risk reward (-20% vs +100%). to be watched closely!!
VSTM - My first sample analysisSTOCH RSI
- Borderline Overbought
ADX and DI
- DI + indicates uptrend
- ADX starting to get up the mid line may indicate strong uptrend
MACD
- MACD and signal indicator have crossed and is going uptrend
Bollinger bands
- show close tunneling may, may signal uptrend
REMARKS
monitor buy signals + analyse fundamentals
This is my first graph analysis
Easy - LONG Verastem! Chart, Technicals, Cash, Upcoming news....
These guys have a COVID trial that starts June 30th and we have yet to see an 8-k or PR for it.
This is a great time to go long and setup for it....We are looking to finally establish 2.05 support...there are a LOT of shorts to come running home if we do so...
First time we will test with a healthier MACD and CMF on the week....STOCH and RSI look great as well....
not a ton of downside risk - if you want, let go if we break the 200day - but other than that this one is way too easy right now.
ENJOY THE FIRE WORKS <3
RSI, MACD indicators are starting to look good?The RSI is near the bottom of its range. The MACD, though in a steep decline is showing that the indicators are closing in. With this stock having a history of sharp gains and losses it could be a really nice set up for some very sharp gains. Also note the huge gap down it took April 27 as there could be a nice gap fill.
Note. I am very new so do not make trades off of my advice. Hopefully someone with some experience will say a few things!
Be Blessed! I am in with a 2.00 average
$VSTM Verastem upside targets Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.